ALKS Alkermes plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALKS

Price (delayed)

$26.17

Market cap

$4.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.97

Enterprise value

$4.41B

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases such as such as schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 by ...

Highlights
The debt has contracted by 4.2% YoY
The EPS has declined by 24% since the previous quarter
Alkermes's net income has decreased by 23% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: ACOR BMY JNJ PFE

Key stats

What are the main financial stats of ALKS
Market
Shares outstanding
164.39M
Market cap
$4.3B
Enterprise value
$4.41B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.12
Price to sales (P/S)
3.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.97
Earnings
Revenue
$1.11B
EBIT
-$154.26M
EBITDA
-$76.4M
Free cash flow
-$17.21M
Per share
EPS
-$0.97
Free cash flow per share
-$0.11
Book value per share
$6.35
Revenue per share
$6.8
TBVPS
$11.21
Balance sheet
Total assets
$1.96B
Total liabilities
$920.23M
Debt
$398.82M
Equity
$1.04B
Working capital
$632.56M
Liquidity
Debt to equity
0.38
Current ratio
2.27
Quick ratio
1.8
Net debt/EBITDA
-1.39
Margins
EBITDA margin
-6.9%
Gross margin
80.4%
Net margin
-14.2%
Operating margin
-12.8%
Efficiency
Return on assets
-8.1%
Return on equity
-14.9%
Return on invested capital
-10.4%
Return on capital employed
-10.5%
Return on sales
-13.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
-1.32%
1 week
-1.69%
1 month
-5.76%
1 year
0.27%
YTD
0.15%
QTD
0.15%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.11B
Gross profit
$893.69M
Operating income
-$142.27M
Net income
-$158.27M
Gross margin
80.4%
Net margin
-14.2%
The net margin has contracted by 25% from the previous quarter
Alkermes's net income has decreased by 23% from the previous quarter
The company's operating margin fell by 22% QoQ
Alkermes's operating income has decreased by 19% from the previous quarter

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
P/E
N/A
P/B
4.12
P/S
3.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.97
The EPS has declined by 24% since the previous quarter
The P/B is 7% higher than the 5-year quarterly average of 3.9 and 4.3% higher than the last 4 quarters average of 4.0
The company's equity fell by 6% YoY
ALKS's P/S is 5% above its last 4 quarters average of 3.7 but 2.5% below its 5-year quarterly average of 4.0
The revenue has contracted by 5% YoY

Efficiency

How efficient is Alkermes business performance
The ROA fell by 25% QoQ
The return on equity has declined by 24% since the previous quarter
The ROS has declined by 17% since the previous quarter
The ROIC has decreased by 16% from the previous quarter

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 113% higher than its total liabilities
Alkermes's total assets has decreased by 3% YoY
The company's total liabilities rose by 2.4% QoQ
The debt is 62% less than the equity
The company's equity fell by 6% YoY
The debt has contracted by 4.2% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.